Table 2.
Cardiac and renal parameters
| Cardiac measures | Females with ERT with indication | Females w/o ERT with indication | Females with ERT without indication | Females w/o ERT without indication | Total |
|---|---|---|---|---|---|
| Dyspnea [n] | 54 (43.6)*** | 14 (18.7) | 0 (0.0) | 1 (4.8) | 69 (30.9) |
| NYHA class [n] | |||||
| none | 29 (28.2) | 31 (45.6)* | 1 (50.0) | 9 (56.3) | 70 (37.0) |
| I | 34 (33.0) | 25 (36.8) | 1 (50.0) | 6 (37.5) | 66 (34.9) |
| II | 27 (26.2) | 11 (16.2) | 0 (0.0) | 1 (6.3) | 39 (20.6) |
| III | 13 (12.6)** | 1 (1.5) | 0 (0.0) | 0 (0.0) | 14 (7.4) |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| LV diastolic diameter [mm] | 45.8 ± 5.5 | 46.2 ± 4.4 | 42.5 ± 3.5 | 46.4 ± 7.2 | 46.0 ± 5.3 |
| LV systolic diameter [mm] | 28.8 ± 6.1 | 28.5 ± 4.7 | 24.0 ± 1.4 | 29.7 ± 4.9 | 28.7 ± 5.5 |
| LVDDi [cm/m2] | 2.79 ± 0.33 | 2.83 ± 0.68 | 2.58 ± 0.12 | 2.78 ± 0.42 | 2.81 ± 0.49 |
| Septal diameter [mm] | 12.3 ± 3.6**** | 9.6 ± 2.0 | 9.5 ± 2.1 | 8.4 ± 1.5 | 11.0 ± 3.3 |
| LVH [n] | 64 (55.7)**** | 14 (18.9) | 0 (0.0) | 0 (0.0) | 78 (37.0) |
| Posterior wall diameter [mm] | 11.3 ± 3.1**** | 9.4 ± 1.9 | 10.5 ± 0.7 | 8.9 ± 1.6 | 10.4 ± 2.8 |
| RWT [cm] | 0.53 ± 0.17**** | 0.41 ± 0.09 | 0.48 ± 0.11 | 0.38 ± 0.10 | 0.47 ± 0.15 |
| ECG abnormalities [n] | 42 (36.5)**** | 7 (10.0) | 1 (50.0) | 1 (5.3) | 51 (24.8) |
| Pacemaker [n] | 18 (14.5)*** | 0 (0.0) | 0 (0.0) | 0 (0.0) | 18 (8.0) |
| Myocardial infarction [n] | 7 (6.9)* | 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (3.5) |
| Renal measures | |||||
| Albumin/creatinine-ratio [mg/gCreatinine] | 48 [0–4773] | 37 [0–734] | 7 [7] | 9 [0–226] | 39 [0–4773] |
| Albuminuria [n] | 60 (61.9) | 30 (58.8) | 0 (0.0) | 6 (40.0) | 96 (58.5) |
| Microalbuminuria (30–300 mg/gCreatinine) [n] | 40 (66.7)* | 27 (90.0) | 0 (0.0) | 6 (100.0) | 73 (76.0) |
| Macroalbuminuria (>300 mg/gCreatinine) [n] | 20 (33.3) | 3 (10.0) | 0 (0.0) | 0 (0.0) | 23 (24.0) |
| Cystatin C [mg/l] | 1.03 ± 0.36**** | 0.78 ± 0.19 | 0.65 ± 0.18 | 0.71 ± 0.09 | 0.90 ± 0.32 |
| eGFRcys [ml/min/1.73 m2]a | 80.4 ± 26.3**** | 103.6 ± 20.7 | 116.1 ± 20.3 | 114.5 ± 13.6 | 92.6 ± 26.7 |
| Creatinine [mg/dl] | 0.99 ± 0.93*** | 0.75 ± 0.15 | 0.64 ± 0.11 | 0.65 ± 0.09 | 0.87 ± 0.71 |
| eGFRcreat [ml/min/1.73 m2]a | 81.2 ± 25.3**** | 98.6 ± 19.1 | 108.8 ± 12.3 | 113.8 ± 12.6 | 90.4 ± 24.8 |
| eGFRcreat < 90 ml/min/1.73 m2 [n] | 82 (66.1)*** | 28 (36.8) | 0 (0.0) | 0 (0.0) | 110 (49.1) |
| Hb [mg/dl] | 13.3 ± 1.0 | 13.4 ± 0.99 | 13.1 ± 0.31 | 13.3 ± 1.1 | 13.3 ± 1.02 |
| Dialysis [n] | 2 (1.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.9) |
| Kidney transplantation [n] | 1 (0.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.5) |
| Manifestations in different organs justifying ERT (per patient) [n] | 2.5 [1–5]**** | 1 [1–3] | - | - | 2 [0–5] |
Categorical data are presented as n and are % of total in parenthesis. Otherwise data is presented as mean ± standard deviation or median [range]. eGFR: estimated glomerular filtration rate (aexcluding patients with dialysis and/or kidney transplant); Hb Hemoglobin. eGFRcreat and eGFRcys are calculated via the CKD-EPI formulas according to Levey et al. 2009 and Inker et al. 2012, respectively. LVDDi: left ventricular diastolic diameter index; LVH: left ventricular hypertrophy (>12 mm septal diameter); NYHA New York Heart Association, RWT relative wall thickness. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001